nodes	percent_of_prediction	percent_of_DWPC	metapath
Propylthiouracil—DBH—nerve—skin cancer	0.0466	0.206	CbGeAlD
Propylthiouracil—TPO—neck—skin cancer	0.0402	0.177	CbGeAlD
Propylthiouracil—Erythema nodosum—Vemurafenib—skin cancer	0.0343	0.0444	CcSEcCtD
Propylthiouracil—Ageusia—Vismodegib—skin cancer	0.0297	0.0384	CcSEcCtD
Propylthiouracil—Pigmentation disorder—Temozolomide—skin cancer	0.0227	0.0294	CcSEcCtD
Propylthiouracil—MPO—endothelium—skin cancer	0.0212	0.0937	CbGeAlD
Propylthiouracil—TPO—lymphoid tissue—skin cancer	0.021	0.0928	CbGeAlD
Propylthiouracil—Traumatic liver injury—Temozolomide—skin cancer	0.0204	0.0263	CcSEcCtD
Propylthiouracil—MPO—blood vessel—skin cancer	0.0196	0.0864	CbGeAlD
Propylthiouracil—Lung infiltration—Bleomycin—skin cancer	0.0192	0.0248	CcSEcCtD
Propylthiouracil—Skin ulcer—Imiquimod—skin cancer	0.0163	0.021	CcSEcCtD
Propylthiouracil—Interstitial pneumonia—Temozolomide—skin cancer	0.0157	0.0203	CcSEcCtD
Propylthiouracil—Vasculitis—Vemurafenib—skin cancer	0.0152	0.0197	CcSEcCtD
Propylthiouracil—Drug fever—Docetaxel—skin cancer	0.0151	0.0195	CcSEcCtD
Propylthiouracil—DBH—female reproductive system—skin cancer	0.0132	0.0584	CbGeAlD
Propylthiouracil—Interstitial lung disease—Bleomycin—skin cancer	0.0127	0.0164	CcSEcCtD
Propylthiouracil—DBH—head—skin cancer	0.0111	0.0488	CbGeAlD
Propylthiouracil—Lymphadenopathy—Imiquimod—skin cancer	0.0108	0.0139	CcSEcCtD
Propylthiouracil—Interstitial lung disease—Temozolomide—skin cancer	0.0107	0.0139	CcSEcCtD
Propylthiouracil—Alopecia—Vismodegib—skin cancer	0.0107	0.0138	CcSEcCtD
Propylthiouracil—Interstitial pneumonia—Docetaxel—skin cancer	0.0104	0.0135	CcSEcCtD
Propylthiouracil—Dysgeusia—Vismodegib—skin cancer	0.0103	0.0133	CcSEcCtD
Propylthiouracil—MPO—connective tissue—skin cancer	0.01	0.0443	CbGeAlD
Propylthiouracil—Dermatitis exfoliative—Imiquimod—skin cancer	0.00974	0.0126	CcSEcCtD
Propylthiouracil—MPO—epithelium—skin cancer	0.00953	0.042	CbGeAlD
Propylthiouracil—MPO—skin of body—skin cancer	0.00907	0.04	CbGeAlD
Propylthiouracil—Liver injury—Temozolomide—skin cancer	0.00902	0.0117	CcSEcCtD
Propylthiouracil—Arthralgia—Vismodegib—skin cancer	0.00894	0.0116	CcSEcCtD
Propylthiouracil—Myalgia—Vismodegib—skin cancer	0.00894	0.0116	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Vemurafenib—skin cancer	0.00814	0.0105	CcSEcCtD
Propylthiouracil—Aplastic anaemia—Dactinomycin—skin cancer	0.00788	0.0102	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00781	0.0101	CcSEcCtD
Propylthiouracil—DBH—lymph node—skin cancer	0.00775	0.0342	CbGeAlD
Propylthiouracil—Dyspepsia—Vismodegib—skin cancer	0.00755	0.00976	CcSEcCtD
Propylthiouracil—MPO—lymphoid tissue—skin cancer	0.00734	0.0324	CbGeAlD
Propylthiouracil—Interstitial lung disease—Docetaxel—skin cancer	0.00713	0.00922	CcSEcCtD
Propylthiouracil—Aplastic anaemia—Temozolomide—skin cancer	0.00712	0.00921	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Imiquimod—skin cancer	0.00694	0.00898	CcSEcCtD
Propylthiouracil—Hepatic failure—Dactinomycin—skin cancer	0.00678	0.00876	CcSEcCtD
Propylthiouracil—Neuritis—Docetaxel—skin cancer	0.00676	0.00874	CcSEcCtD
Propylthiouracil—Alopecia—Vemurafenib—skin cancer	0.00659	0.00852	CcSEcCtD
Propylthiouracil—Haemoglobin—Imiquimod—skin cancer	0.00639	0.00826	CcSEcCtD
Propylthiouracil—Haemorrhage—Imiquimod—skin cancer	0.00636	0.00822	CcSEcCtD
Propylthiouracil—Dysgeusia—Vemurafenib—skin cancer	0.00636	0.00822	CcSEcCtD
Propylthiouracil—Ageusia—Docetaxel—skin cancer	0.00623	0.00805	CcSEcCtD
Propylthiouracil—Hepatic failure—Temozolomide—skin cancer	0.00613	0.00793	CcSEcCtD
Propylthiouracil—Pruritus—Vismodegib—skin cancer	0.00607	0.00784	CcSEcCtD
Propylthiouracil—MPO—head—skin cancer	0.00592	0.0261	CbGeAlD
Propylthiouracil—Dermatitis exfoliative—Temozolomide—skin cancer	0.00584	0.00755	CcSEcCtD
Propylthiouracil—Alopecia—Imiquimod—skin cancer	0.00562	0.00727	CcSEcCtD
Propylthiouracil—Myalgia—Vemurafenib—skin cancer	0.00553	0.00715	CcSEcCtD
Propylthiouracil—Arthralgia—Vemurafenib—skin cancer	0.00553	0.00715	CcSEcCtD
Propylthiouracil—Vomiting—Vismodegib—skin cancer	0.00545	0.00705	CcSEcCtD
Propylthiouracil—Rash—Vismodegib—skin cancer	0.00541	0.00699	CcSEcCtD
Propylthiouracil—Dermatitis—Vismodegib—skin cancer	0.0054	0.00698	CcSEcCtD
Propylthiouracil—Nausea—Vismodegib—skin cancer	0.00509	0.00659	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00483	0.00624	CcSEcCtD
Propylthiouracil—Myalgia—Imiquimod—skin cancer	0.00471	0.00609	CcSEcCtD
Propylthiouracil—Arthralgia—Imiquimod—skin cancer	0.00471	0.00609	CcSEcCtD
Propylthiouracil—Haemoglobin—Bleomycin—skin cancer	0.00454	0.00587	CcSEcCtD
Propylthiouracil—Oedema—Imiquimod—skin cancer	0.00452	0.00584	CcSEcCtD
Propylthiouracil—Haemorrhage—Bleomycin—skin cancer	0.00452	0.00584	CcSEcCtD
Propylthiouracil—Agranulocytosis—Dactinomycin—skin cancer	0.00438	0.00566	CcSEcCtD
Propylthiouracil—Hepatitis—Dactinomycin—skin cancer	0.00421	0.00545	CcSEcCtD
Propylthiouracil—Body temperature increased—Vemurafenib—skin cancer	0.00419	0.00542	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Temozolomide—skin cancer	0.00416	0.00538	CcSEcCtD
Propylthiouracil—MPO—lymph node—skin cancer	0.00414	0.0183	CbGeAlD
Propylthiouracil—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00412	0.00532	CcSEcCtD
Propylthiouracil—Hepatic failure—Docetaxel—skin cancer	0.00408	0.00527	CcSEcCtD
Propylthiouracil—Paraesthesia—Imiquimod—skin cancer	0.00406	0.00525	CcSEcCtD
Propylthiouracil—Somnolence—Imiquimod—skin cancer	0.00402	0.00519	CcSEcCtD
Propylthiouracil—Alopecia—Bleomycin—skin cancer	0.00399	0.00516	CcSEcCtD
Propylthiouracil—Dyspepsia—Imiquimod—skin cancer	0.00398	0.00514	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Fluorouracil—skin cancer	0.00383	0.00496	CcSEcCtD
Propylthiouracil—Haemoglobin—Temozolomide—skin cancer	0.00383	0.00495	CcSEcCtD
Propylthiouracil—Hepatitis—Temozolomide—skin cancer	0.00381	0.00493	CcSEcCtD
Propylthiouracil—Haemorrhage—Temozolomide—skin cancer	0.00381	0.00493	CcSEcCtD
Propylthiouracil—Pruritus—Vemurafenib—skin cancer	0.00375	0.00485	CcSEcCtD
Propylthiouracil—Alopecia—Dactinomycin—skin cancer	0.00372	0.00481	CcSEcCtD
Propylthiouracil—Agranulocytosis—Fluorouracil—skin cancer	0.00365	0.00472	CcSEcCtD
Propylthiouracil—Urticaria—Imiquimod—skin cancer	0.00359	0.00464	CcSEcCtD
Propylthiouracil—Body temperature increased—Imiquimod—skin cancer	0.00357	0.00462	CcSEcCtD
Propylthiouracil—Haemoglobin—Fluorouracil—skin cancer	0.00353	0.00456	CcSEcCtD
Propylthiouracil—Leukopenia—Bleomycin—skin cancer	0.00352	0.00455	CcSEcCtD
Propylthiouracil—Haemorrhage—Fluorouracil—skin cancer	0.00351	0.00454	CcSEcCtD
Propylthiouracil—Vomiting—Vemurafenib—skin cancer	0.00337	0.00436	CcSEcCtD
Propylthiouracil—Alopecia—Temozolomide—skin cancer	0.00337	0.00435	CcSEcCtD
Propylthiouracil—Myalgia—Bleomycin—skin cancer	0.00335	0.00433	CcSEcCtD
Propylthiouracil—Rash—Vemurafenib—skin cancer	0.00334	0.00432	CcSEcCtD
Propylthiouracil—Dermatitis—Vemurafenib—skin cancer	0.00334	0.00432	CcSEcCtD
Propylthiouracil—Headache—Vemurafenib—skin cancer	0.00332	0.00429	CcSEcCtD
Propylthiouracil—Leukopenia—Dactinomycin—skin cancer	0.00328	0.00425	CcSEcCtD
Propylthiouracil—Dysgeusia—Temozolomide—skin cancer	0.00325	0.0042	CcSEcCtD
Propylthiouracil—Oedema—Bleomycin—skin cancer	0.00321	0.00415	CcSEcCtD
Propylthiouracil—Pruritus—Imiquimod—skin cancer	0.0032	0.00413	CcSEcCtD
Propylthiouracil—Nausea—Vemurafenib—skin cancer	0.00315	0.00407	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Bleomycin—skin cancer	0.00314	0.00406	CcSEcCtD
Propylthiouracil—Myalgia—Dactinomycin—skin cancer	0.00312	0.00404	CcSEcCtD
Propylthiouracil—Alopecia—Fluorouracil—skin cancer	0.0031	0.00401	CcSEcCtD
Propylthiouracil—Oedema—Dactinomycin—skin cancer	0.00299	0.00387	CcSEcCtD
Propylthiouracil—Vertigo—Temozolomide—skin cancer	0.00298	0.00385	CcSEcCtD
Propylthiouracil—Leukopenia—Temozolomide—skin cancer	0.00297	0.00384	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Dactinomycin—skin cancer	0.00293	0.00379	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00292	0.00378	CcSEcCtD
Propylthiouracil—Paraesthesia—Bleomycin—skin cancer	0.00288	0.00373	CcSEcCtD
Propylthiouracil—Vomiting—Imiquimod—skin cancer	0.00287	0.00371	CcSEcCtD
Propylthiouracil—Rash—Imiquimod—skin cancer	0.00285	0.00368	CcSEcCtD
Propylthiouracil—Dermatitis—Imiquimod—skin cancer	0.00285	0.00368	CcSEcCtD
Propylthiouracil—Headache—Imiquimod—skin cancer	0.00283	0.00366	CcSEcCtD
Propylthiouracil—Arthralgia—Temozolomide—skin cancer	0.00282	0.00365	CcSEcCtD
Propylthiouracil—Myalgia—Temozolomide—skin cancer	0.00282	0.00365	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Docetaxel—skin cancer	0.00277	0.00358	CcSEcCtD
Propylthiouracil—Jaundice—Docetaxel—skin cancer	0.00275	0.00356	CcSEcCtD
Propylthiouracil—Leukopenia—Fluorouracil—skin cancer	0.00274	0.00354	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00273	0.00353	CcSEcCtD
Propylthiouracil—Oedema—Temozolomide—skin cancer	0.00271	0.0035	CcSEcCtD
Propylthiouracil—Nausea—Imiquimod—skin cancer	0.00268	0.00347	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Temozolomide—skin cancer	0.00265	0.00343	CcSEcCtD
Propylthiouracil—Agranulocytosis—Docetaxel—skin cancer	0.00263	0.00341	CcSEcCtD
Propylthiouracil—Myalgia—Fluorouracil—skin cancer	0.0026	0.00336	CcSEcCtD
Propylthiouracil—Urticaria—Bleomycin—skin cancer	0.00255	0.0033	CcSEcCtD
Propylthiouracil—Haemoglobin—Docetaxel—skin cancer	0.00255	0.00329	CcSEcCtD
Propylthiouracil—Body temperature increased—Bleomycin—skin cancer	0.00254	0.00328	CcSEcCtD
Propylthiouracil—Haemorrhage—Docetaxel—skin cancer	0.00253	0.00328	CcSEcCtD
Propylthiouracil—Hepatitis—Docetaxel—skin cancer	0.00253	0.00328	CcSEcCtD
Propylthiouracil—Oedema—Fluorouracil—skin cancer	0.00249	0.00323	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00247	0.00319	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Fluorouracil—skin cancer	0.00244	0.00316	CcSEcCtD
Propylthiouracil—Paraesthesia—Temozolomide—skin cancer	0.00243	0.00314	CcSEcCtD
Propylthiouracil—Somnolence—Temozolomide—skin cancer	0.00241	0.00311	CcSEcCtD
Propylthiouracil—Dyspepsia—Temozolomide—skin cancer	0.00238	0.00308	CcSEcCtD
Propylthiouracil—Body temperature increased—Dactinomycin—skin cancer	0.00237	0.00306	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00227	0.00294	CcSEcCtD
Propylthiouracil—Pruritus—Bleomycin—skin cancer	0.00227	0.00294	CcSEcCtD
Propylthiouracil—Paraesthesia—Fluorouracil—skin cancer	0.00224	0.0029	CcSEcCtD
Propylthiouracil—Alopecia—Docetaxel—skin cancer	0.00224	0.0029	CcSEcCtD
Propylthiouracil—Somnolence—Fluorouracil—skin cancer	0.00222	0.00287	CcSEcCtD
Propylthiouracil—Dyspepsia—Fluorouracil—skin cancer	0.0022	0.00284	CcSEcCtD
Propylthiouracil—Dysgeusia—Docetaxel—skin cancer	0.00216	0.00279	CcSEcCtD
Propylthiouracil—Urticaria—Temozolomide—skin cancer	0.00215	0.00278	CcSEcCtD
Propylthiouracil—Body temperature increased—Temozolomide—skin cancer	0.00214	0.00277	CcSEcCtD
Propylthiouracil—Vomiting—Bleomycin—skin cancer	0.00204	0.00264	CcSEcCtD
Propylthiouracil—Rash—Bleomycin—skin cancer	0.00202	0.00262	CcSEcCtD
Propylthiouracil—Dermatitis—Bleomycin—skin cancer	0.00202	0.00261	CcSEcCtD
Propylthiouracil—Urticaria—Fluorouracil—skin cancer	0.00198	0.00256	CcSEcCtD
Propylthiouracil—Leukopenia—Docetaxel—skin cancer	0.00197	0.00255	CcSEcCtD
Propylthiouracil—Body temperature increased—Fluorouracil—skin cancer	0.00197	0.00255	CcSEcCtD
Propylthiouracil—Pruritus—Temozolomide—skin cancer	0.00192	0.00248	CcSEcCtD
Propylthiouracil—Nausea—Bleomycin—skin cancer	0.00191	0.00247	CcSEcCtD
Propylthiouracil—Vomiting—Dactinomycin—skin cancer	0.0019	0.00246	CcSEcCtD
Propylthiouracil—Rash—Dactinomycin—skin cancer	0.00189	0.00244	CcSEcCtD
Propylthiouracil—Myalgia—Docetaxel—skin cancer	0.00188	0.00243	CcSEcCtD
Propylthiouracil—Arthralgia—Docetaxel—skin cancer	0.00188	0.00243	CcSEcCtD
Propylthiouracil—Oedema—Docetaxel—skin cancer	0.0018	0.00233	CcSEcCtD
Propylthiouracil—Nausea—Dactinomycin—skin cancer	0.00178	0.0023	CcSEcCtD
Propylthiouracil—Pruritus—Fluorouracil—skin cancer	0.00176	0.00228	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Docetaxel—skin cancer	0.00176	0.00228	CcSEcCtD
Propylthiouracil—Vomiting—Temozolomide—skin cancer	0.00172	0.00223	CcSEcCtD
Propylthiouracil—Rash—Temozolomide—skin cancer	0.00171	0.00221	CcSEcCtD
Propylthiouracil—Dermatitis—Temozolomide—skin cancer	0.00171	0.00221	CcSEcCtD
Propylthiouracil—Headache—Temozolomide—skin cancer	0.0017	0.00219	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00164	0.00212	CcSEcCtD
Propylthiouracil—Paraesthesia—Docetaxel—skin cancer	0.00162	0.00209	CcSEcCtD
Propylthiouracil—Nausea—Temozolomide—skin cancer	0.00161	0.00208	CcSEcCtD
Propylthiouracil—Somnolence—Docetaxel—skin cancer	0.0016	0.00207	CcSEcCtD
Propylthiouracil—Vomiting—Fluorouracil—skin cancer	0.00159	0.00205	CcSEcCtD
Propylthiouracil—Dyspepsia—Docetaxel—skin cancer	0.00158	0.00205	CcSEcCtD
Propylthiouracil—Rash—Fluorouracil—skin cancer	0.00157	0.00203	CcSEcCtD
Propylthiouracil—Dermatitis—Fluorouracil—skin cancer	0.00157	0.00203	CcSEcCtD
Propylthiouracil—Headache—Fluorouracil—skin cancer	0.00156	0.00202	CcSEcCtD
Propylthiouracil—Nausea—Fluorouracil—skin cancer	0.00148	0.00192	CcSEcCtD
Propylthiouracil—Body temperature increased—Docetaxel—skin cancer	0.00142	0.00184	CcSEcCtD
Propylthiouracil—Pruritus—Docetaxel—skin cancer	0.00127	0.00165	CcSEcCtD
Propylthiouracil—Vomiting—Docetaxel—skin cancer	0.00114	0.00148	CcSEcCtD
Propylthiouracil—Rash—Docetaxel—skin cancer	0.00114	0.00147	CcSEcCtD
Propylthiouracil—Dermatitis—Docetaxel—skin cancer	0.00113	0.00147	CcSEcCtD
Propylthiouracil—Headache—Docetaxel—skin cancer	0.00113	0.00146	CcSEcCtD
Propylthiouracil—Nausea—Docetaxel—skin cancer	0.00107	0.00138	CcSEcCtD
